2023
Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial
McKee S, Lawrence D, Saccone P, McRae T, Anthenelli R. Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial. Drug And Alcohol Dependence Reports 2023, 8: 100177. PMID: 37520849, PMCID: PMC10372180, DOI: 10.1016/j.dadr.2023.100177.Peer-Reviewed Original ResearchNeuropsychiatric adverse eventsCessation outcomesContinuous abstinenceAdverse eventsPsychiatric cohortPsychiatric statusLower oddsEfficacy of vareniclineSmoking cessation medicationsPoint prevalence abstinenceHigher baseline levelsSex effectsLogistic regression modelsEAGLES trialCessation medicationsBaseline characteristicsSmoking historyMedication useNicotine patchPoint prevalenceStudy treatmentBaseline variablesBaseline cigarettesAbstinence outcomesSignificant interaction
2019
Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers.
Verplaetse TL, Roberts W, Moore KE, Peltier MR, Oberleitner LM, McKee SA. Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers. Journal Of Clinical Psychopharmacology 2019, 39: 124-128. PMID: 30707118, PMCID: PMC6391212, DOI: 10.1097/jcp.0000000000001004.Peer-Reviewed Original ResearchConceptsAdult daily smokersDoses of guanfacineAdverse eventsMedication levelsDaily smokersTobacco cravingTreatment-emergent adverse eventsExtended-release formulationSimilar pharmacokinetic profileAttention deficit hyperactivity disorderDry mouthLast doseMigraine prophylaxisBlood pressureHeroin withdrawalStable dosingDose equivalencyHeart rateER formulationSmoking outcomesGuanfacinePharmacokinetic profileDrug AdministrationVital signsHyperactivity disorder
2016
Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. Journal Of Addiction Medicine 2016, 10: 166-173. PMID: 27159341, PMCID: PMC4880525, DOI: 10.1097/adm.0000000000000208.Peer-Reviewed Original ResearchConceptsAlcohol use disorderEffects of vareniclineAlcohol consumptionUse disordersVarenicline doseD dosePlasma levelsDose of vareniclineDoses of vareniclineFrequency of insomniaPlacebo-controlled investigationHigher plasma levelsDose of alcoholAlcohol Self-AdministrationSelf-administration periodMedication pretreatmentAdverse eventsEdition criteriaVareniclineLow doseSide effectsAlcohol cravingMeeting criteriaPhysiologic responsesAlcohol-related outcomes
2009
Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers
McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E. Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers. Biological Psychiatry 2009, 66: 185-190. PMID: 19249750, PMCID: PMC2863311, DOI: 10.1016/j.biopsych.2009.01.029.Peer-Reviewed Original ResearchConceptsHeavy drinking smokersSelf-administration periodAlcohol consumptionPartial nicotinic agonistPlacebo-controlled investigationEffects of vareniclineReduced ethanol intakeAlcohol Self-AdministrationAlcohol use disorderNicotinic acetylcholine receptorsMedication pretreatmentAdverse eventsNumber of drinksPreclinical evidenceAdditional drinkEthanol intakeTobacco dependenceDaily smokersPriming doseVareniclineComorbid disordersNicotinic agonistsUse disordersPriming drinkPotential treatment